glp-1 agonist cost costs rise, but there are ways to save on weight-loss drugs Growth, Volume, Price: The Skinny

How To Avoid Lectins Dr

Ciba Found Symp

Safety Considerations and Future Outlook As with all pharmacotherapy for obesity and T2D, establishing cardiovascular safety and demonstrating improvements in meaningful clinical outcomes will be essential, particularly as cardiovascular outcome trials have not yet been completed with multi-agonists (although data are expected soon for tirzepatide: SURPASS-CVOT [T2D] in 2025

Jared Espley: Europa is a really interesting place

The edible portion primarily consists of water (~74%), protein (~12%), lipid (~12%), carbohydrates ( 90%), efficiently incorporated into plasma high-density lipoproteins, and play key roles in lipid metabolism regulation

While short-term use may improve insulin sensitivity, chronic exposure can worsen metabolic conditionsespecially in those already struggling with blood sugar control